Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 4/20 | 0.35 |
| ▸ | DRD3 | P35462 | 4/20 | 0.35 |
| ▸ | LIPE | Q05469 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29695363 | 1.00 | LPL (0.37) | LPLLIPGDRD2DRD3LIPE | |
| SCHEMBL13043663 | 0.89 | LPL (0.40) | LPLLIPGLIPECXCR2DGAT1 | |
| SCHEMBL18174184 | 0.89 | LPL (0.40) | LPLLIPG | |
| SCHEMBL26336096 | 0.86 | LPL (0.39) | LPLLIPGHTR1AHTR2B | |
| SCHEMBL262387 | 0.84 | LPL (0.37) | LPLLIPGLIPEDRD4CXCR2 | |
| SCHEMBL29534512 | 0.84 | LPL (0.37) | LPLLIPGLIPEDRD4CXCR2 | |
| SCHEMBL29079901 | 0.83 | LPL (0.36) | LPLLIPGLIPEKDM4ECXCR2 | |
| SCHEMBL262784 | 0.83 | LPL (0.36) | LPLLIPGLIPEKDM4ECXCR2 | |
| SCHEMBL23680880 | 0.82 | ALDH1A1 (0.43) | LPLLIPGKDM4EHTR2B | |
| SCHEMBL25437909 | 0.81 | LMNA (0.46) | LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
| CN-114787167-A | Compounds and compositions for the treatment of parasitic diseases | 诺华股份有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021078120-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-29 | — | — | WO | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597733-B2 | Compounds and compositions for the treatment of parasitic diseases | ABCB11, SQLE, FURIN | LPL 3912/4885LIPG 3497/4885DRD2 4723/4885 |
| US-20210115065-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | ABCB11, SQLE, FURIN | LPL 3912/4885LIPG 3497/4885DRD2 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.